FIGURE 5.
XBJ treatment increases the viability and GSK-3β (Ser9) expression of RAW264.7 cells (A) Concentration screening for XBJ cell experiments. (B) XBJ improved the viability of LPS-induced sepsis ALI cells (C) Representative images of GSK-3β immunofluorescence in vitro. (D) The expression of GSK-3β in cell with ALI. Con: control group without LPS treatment; LPS: model group with LPS treatment; 100-XBJ: group with LPS treatment + XBJ injection diluted 100 times; 50-XBJ: group with LPS treatment + XBJ injection diluted 50 times; 25-XBJ: group with LPS treatment + XBJ injection diluted 25 times. Compared with the control group, #p < 0.05, ##p < 0.01 were considered to be significant; Compared with the CLP group, *p < 0.05, **p < 0.01 were considered to be significant. Data are expressed as mean ± SD.